MARKET WIREStockInvest.us • 18h ago
Bicycle Therapeutics Stock Price Forecast. Should You Buy BCYC?StockInvest.us report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
Why BCYC Stock dropped -4.19% Today — RQD Quant Desk Flash
$3.66 -4.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.63
Bicycle Therapeutics plc (BCYC) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $256.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BCYC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BCYC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Bicycle Therapeutics plc (NASDAQ: BCYC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $3.66 (-4.19% 1D, market cap $256.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCYC ranks #979 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BCYC compare to LRMR and GLSI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCYC carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LRMR (Larimar Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $256.6M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, BCYC leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BCYC?
▼
Per BCYC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001761612), Bicycle Therapeutics plc generated $72.6M in revenue (+105.8% YoY), -$219.0M in net income, and -$252.0M in free cash flow against $717.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.63 (-0.94%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCYC)Realized 20D OHLCV Swing Band: ±11.4%
Deterministic 5-Pillar Attribution (20/100 Composite)
🔍 WHY BCYC SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+5/20 pts (25% of score)
20D Institutional Volume Accumulation (±11.4% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (25% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.63-0.8% Next Q
15
Q2 (-2Q)Grade E$3.60+5% Next Q
16
Q3 (-1Q)Grade E$3.78-3.2% Next Q
18
CurrentGrade E$3.66-11.8% Hist 90D α
20
Trajectory: E (15) → E (20)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BCYC Turnaround Squeeze
While BCYC currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.81) and Max Pain ($3.84) forces dealer call-delta covering toward $8.52.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCYC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BCYC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BCYC Stock dropped -4.19% Today — RQD Quant Desk Flash
Bicycle Therapeutics plc (BCYC) dropped -4.19% to $3.66, trading at 7% of its 52-week range ($3.33 – $8.11). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 7% of its 52-week range ($3.33 – $8.11) with RSI-14 at 48.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.4% around $3.66 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BCYC Headlines & Catalysts
MARKET WIREYahoo Finance UK • 21h ago
Bicycle Therapeutics plc (BCYC) Seasonal returns chartYahoo Finance UK report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHTradingView • 1d ago
Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $9.86, Implies 154% UpsideTradingView report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
To cover vesting taxes, Bicycle Therapeutics (BCYC) director sells 3,431 shares.Stock Titan report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth CarefullySimply Wall St report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHKalkine • 1d ago
Bicycle Therapeutics (NASDAQ:BCYC) Narrows Net Loss and Pivots Pipeline Toward Radioligand Therapies in Q3 2026Kalkine report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Lobbying Update: $150,000 of BICYCLE THERAPEUTICS lobbying was just disclosedQuiver Quantitative report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
FDA gives Bicycle's pancreatic cancer drug a rare-disease designationStock Titan report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsCAMBRIDGE, England & BOSTON, October 29, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycl
CATALYSTBenzinga • 5d ago
Bicycle Therapeutics Q3 EPS $(0.15) Beats $(0.48) Estimate, Sales $34.057M Beat $6.069M EstimateBicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.48) by 68.75 percent. This is a 82.35 percent increase over losses of $(0.85) per share
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCYC)
- ✓Walkthrough of BCYC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BCYC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.91%▼ DESCENDING CHANNEL
2026-11-03O $3.82H $3.82L $3.66C $3.66VOL 348.6K
RES: $4.12SUP: $3.15SMA50: $3.81SMA200: $4.54
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BCYC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +105.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BCYC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BCYC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BCYC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCYC)
Health Care Rank #979 of 1016
⚔️ LRMR vs BCYC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BCYC vs. LRMR, GLSI, AMRN, ABEO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicycle Therapeutics plc (BCYC) ranks #979 by composite RQD confidence (20/100, grade E) and #536 by equity capitalization ($256.5M). Within this direct 5-issuer industry benchmark cohort, BCYC leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with BCYC at 20/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCYC
ACTIVE
Bicycle Therapeutics plc | E | 20/100 | — | — | -35.0% | -4.19% | $256.5M | Benchmark Subject |
| LRMR Larimar Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -7.49% | $256.6M | /lrmr-vs-bcyc → |
| GLSI Greenwich LifeSciences Inc. | E | 31/100 | — | — | -35.0% | -8.37% | $255.5M | /glsi-vs-bcyc → |
| AMRN Amarin Corporation plc | E | 32/100 | — | 56.6% | -12.2% | -4.91% | $249.9M | /amrn-vs-bcyc → |
| ABEO Abeona Therapeutics Inc. | E | 23/100 | — | 73.7% | -35.0% | -4.61% | $248.8M | /abeo-vs-bcyc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001761612In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicycle Therapeutics plc (BCYC) reported GAAP revenue of $72.6M (+105.8% vs. FY2024 revenue of $35.3M , and +169.1% cumulative change since FY2023) , GAAP net income of -$219.0M, operating cash flow of -$249.7M, and free cash flow of -$252.0M (-51.9% YoY). On the balance sheet, BCYC closed FY2025 with $717.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $72.6M | -$219.0M | -$249.7M | -$252.0M | $717.6M | — |
| FY2024 (FY) | 2024-12-31 | $35.3M | -$169.0M | -$164.7M | -$166.0M | $956.9M | — |
| FY2023 (FY) | 2023-12-31 | $27.0M | -$180.7M | -$60.6M | -$60.6M | — | — |
3. BCYC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BCYC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Bicycle Therapeutics plc (NASDAQ: BCYC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $3.66 (-4.19% 1D, market cap $256.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCYC ranks #979 in composite RQD confidence.
How does BCYC compare to LRMR and GLSI in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCYC carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LRMR (Larimar Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $256.6M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, BCYC leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BCYC?
Per BCYC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001761612), Bicycle Therapeutics plc generated $72.6M in revenue (+105.8% YoY), -$219.0M in net income, and -$252.0M in free cash flow against $717.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BCYC trading relative to its 50-day, 200-day, and 52-week technical levels?
BCYC last traded at $3.66 (-4.19% on volume of 348,594 shares), positioning the stock -3.94% below its 50-day simple moving average ($3.81) and -19.38% below its 200-day simple moving average ($4.54). Across its 52-week range of $3.33 to $8.11, BCYC sits at the 6.9% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($3.24 to $4.08).
BCYC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BCYC stock moving today?
Why BCYC Stock dropped -4.19% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 20/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BCYC — Bicycle Therapeutics plc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:39:36Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BCYC carries an RQD Score of 21 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 2 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale/13F flow scores 6 of 20 for institutional accumulation and options positioning, the second-weakest pillar after fundamentals. Insider conviction scores 3 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 5 of 20 with a beta of 1.0 and noted sector sensitivity. Forensic balance sheet scores 5 of 20, reflecting an Altman Z of 0.2, a Piotroski F of 2/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, these pillars point to a profile where the primary upside case would have to rest on a future inflection rather than current economics. The price of 3.82 sits within a 52-week range of $3.33 to $8.48, and the market cap of $267.4M is small relative to the reported operating loss of $-247.1M in FY 2025. Valuation multiples such as P/E and EV/EBITDA are not available in source data, so relative valuation cannot be assessed from these sources. The weak forensic and insider readings mean the score offers little independent confirmation of an upside thesis. Any investment case would depend on information outside this dataset.
Recent Catalysts & News Wire Analysis
Per the recent news feed, the items cover several themes:
- Analyst target action (RED / RISK WATCH): A TradingView report references a 12-month price target cut to $9.86, which it frames as implying 154% upside.
- Insider transaction (YELLOW / MARKET WIRE): A Stock Titan report describes a director selling 3,431 shares to cover vesting taxes.
- Strategic pivot (RED / RISK WATCH): A Kalkine report describes a narrowed net loss and a pipeline pivot toward radioligand therapies in Q3 2026.
- Positive catalyst (GREEN / CATALYST): A Simply Wall St report, titled around driving business growth carefully, is tagged as a catalyst.
- General market coverage (YELLOW / MARKET WIRE): StockInvest.us and Yahoo Finance UK items cover market action and seasonal returns without specific new facts.
The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are BCYC's products, clinical programs, and revenue sources, given that the source data describes only the sector and industry?
- What drove the FY 2025 revenue increase to $72.6M, and what portion is recurring versus one-time?
- What is the current cash runway given cash of $628.1M against an FY 2025 FCF of $-252.0M, and what is the stated debt position?
- What are the terms and timing of the reported pipeline pivot toward radioligand therapies?
- What institutional, insider, and analyst positioning exists, since the holders and analyst sections are empty?
BCYC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bicycle Therapeutics plc (BCYC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 18h ago
Bicycle Therapeutics Stock Price Forecast. Should You Buy BCYC? StockInvest.us report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 21h ago
Bicycle Therapeutics plc (BCYC) Seasonal returns chart Yahoo Finance UK report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH TradingView • 1d ago
Bicycle Therapeutics plc Stock 12‑Month Price Target Cut to $9.86, Implies 154% Upside TradingView report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
To cover vesting taxes, Bicycle Therapeutics (BCYC) director sells 3,431 shares. Stock Titan report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth Carefully Simply Wall St report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Kalkine • 1d ago
Bicycle Therapeutics (NASDAQ:BCYC) Narrows Net Loss and Pivots Pipeline Toward Radioligand Therapies in Q3 2026 Kalkine report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Lobbying Update: $150,000 of BICYCLE THERAPEUTICS lobbying was just disclosed Quiver Quantitative report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
FDA gives Bicycle's pancreatic cancer drug a rare-disease designation Stock Titan report covering Bicycle Therapeutics plc (BCYC) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BCYC Bull vs. Bear Conversation Board — What's Your Call at $3.66?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCYC 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $3.36 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BCYC (E • RQD 21/100) a Buy at $3.82?
Welcome to the BCYC (Bicycle Therapeutics plc) Roar Pit. Current RQD Composite is 21/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $3.21 (-16.0%)
Spot @ $3.82 Pump the brakes on BCYC — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BCYC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Bicycle Therapeutics plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $4.74 (+24.1%)
Spot @ $3.82 BCYC cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BCYC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.82 (52-wk range $3.33 - $8.48), any beat on forward guidance forces shorts and underweight funds to chase.